echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > MSD 2.7 billion US dollars for a new generation of in-process therapy

    MSD 2.7 billion US dollars for a new generation of in-process therapy

    • Last Update: 2019-12-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    MSD announced on December 10 that MSD will acquire all the public shares of arqule at a price of $20 / share through its subsidiaries, with a total amount of about $2.7 billion The main candidate drug for arqule to be obtained by mosadon is ARQ 531 ARQ 531, as a novel oral Burton tyrosine kinase (Btk) inhibitor, is currently undergoing phase 2 dose expansion of B-cell malignant tumors Btk inhibition has been shown to block B cell receptor signaling, which is essential for the survival and proliferation of leukemic cells in many B cell malignancies Arq531 is a highly selective and reversible inhibitor, which can block the wild-type Btk and c481s mutant enzymes This enzyme is usually related to the resistance to other Btk inhibitors In early clinical trials, arq531 was used to treat patients with recurrent or refractory chronic lymphoblastic leukemia (CLL) and Richter's transformation, showing controllable safety and early signs of antitumor activity The results of phase 1 clinical trial were presented at the 61st annual conference and exposition of American Society of Hematology (ash) held in Orlando, Florida on December 9, 2019 A total of 47 patients with recurrent / refractory B-cell cancer received different doses of ARQ 531 The dose escalation test showed that 65 mg QD once a day (65 mg QD) would be the recommended dose for phase 2 clinical trials At doses > 65 mg QD, 8 of the 9 CLL patients who could be evaluated achieved partial remission, and 7 of the 8 patients who achieved remission carried the btk-c481s mutation In addition, 100% (5 / 5) of CLL patients who were able to receive the third scan had sustained partial remission, and they were still receiving treatment At present, three Btk inhibitors have been listed in the world, namely, ibotini (IBV / Johnson), acatini (AstraZeneca) and zebotini (Baiji Shenzhou), with a market size of more than 6 billion US dollars B-cell cancer patients will be the ultimate beneficiaries of the BTK inhibitor development iteration, and they will have more treatment options Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.